This Article Full Text (PDF) References Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by Rascu, A. Articles by Manger, B. Search for Related Content PubMed PubMed Citation Articles by Rascu, A. Articles by Manger, B. Social Bookmarking                         What's this?

Review : Osteonecrosis in systemic lupus erythematosus, steroid-induced or a lupus-dependent manifestation?

Medizinische Klinik mit Poliklinik der Universität Erlangen, Krankenhausstr. 12, D-91054 Erlangen, Germany

K. Manger

Medizinische Klinik mit Poliklinik der Universität Erlangen, Krankenhausstr. 12, D-91054 Erlangen, Germany

H-G. Kraetsch

Medizinische Klinik mit Poliklinik der Universität Erlangen, Krankenhausstr. 12, D-91054 Erlangen, Germany

JR Kalden

Medizinische Klinik mit Poliklinik der Universität Erlangen, Krankenhausstr. 12, D-91054 Erlangen, Germany

B. Manger

Medizinische Klinik mit Poliklinik der Universität Erlangen, Krankenhausstr. 12, D-91054 Erlangen, Germany

Osteonecrosis (ON) is a well-known complication in patients with systemic lupus erythema tosus (SLE) often associated with steroid therapy. In a cohort of 280 SLE patients followed over the last 10 years, seven patients developed symptomatic ON, one of them after septic arthritis of the hip. Two other patients developed ON several years after discontinuing steroids. One patient developed ON of both humeral and femoral heads within a few months after the diagnosis of SLE. When we compared the cumulative steroid doses taken by our patients with those described in other reports (43 700 mg and 45 300 mg, respectively), our patients received less steroids (38 834 mg). We found no increased fre quency of Raynaud's phenomenon, leukopenia, anti-phospholipid antibodies, or a flare of SLE activity in our patients with ON, factors which have been reported to be associated with ON. Various pathogenic mechanisms, which could lead to ON in SLE patients are discussed.

Key Words: systemic lupus erythematosus • osteonecrosis

Lupus, Vol. 5, No. 4, 323-327 (1996)
DOI: 10.1177/096120339600500414


CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter    What's this?

This article has been cited by other articles:

				S.C.M.S. Fialho, E. Bonfa, L.F. Vitule, E. D'Amico, V. Caparbo, S. Gualandro, and R.M.R. Pereira Disease activity as a major risk factor for osteonecrosis in early systemic lupus erythematosus Lupus, April 1, 2007; 16(4): 239 - 244. [Abstract] [PDF]

				R Prasad, D Ibanez, D Gladman, and M Urowitz The role of non-corticosteroid related factors in osteonecrosis (ON) in systemic lupus erythematosus: a nested case-control study of inception patients Lupus, March 1, 2007; 16(3): 157 - 162. [Abstract] [PDF]

				K Nagasawa, Y Tada, S Koarada, H Tsukamoto, T Horiuchi, S Yoshizawa, K Murai, A Ueda, Y Haruta, and A Ohta Prevention of steroid-induced osteonecrosis of femoral head in systemic lupus erythematosus by anti-coagulant Lupus, June 1, 2006; 15(6): 354 - 357. [Abstract] [PDF]

				K Nagasawa, Y Tada, S Koarada, T Horiuchi, H Tsukamoto, K Murai, A Ueda, S Yoshizawa, and A Ohta Very early development of steroid-associated osteonecrosis of femoral head in systemic lupus erythematosus: prospective study by MRI Lupus, May 1, 2005; 14(5): 385 - 390. [Abstract] [PDF]

				K Oinuma, Y Harada, Y Nawata, K Takabayashi, I Abe, K Kamikawa, and H Moriya Osteonecrosis in patients with systemic lupus erythematosus develops very early after starting high dose corticosteroid treatment Ann Rheum Dis, December 1, 2001; 60(12): 1145 - 1148. [Abstract] [Full Text] [PDF]

				M. Y. MOK and D. A ISENBERG Avascular necrosis of a single vertebral body, an atypical site of disease in a patient with SLE and secondary APLS Ann Rheum Dis, June 1, 2000; 59(6): 490e - 490. [Full Text]

				A Zonana-Nacach, A Camargo-Coronel, P Yanez, M de Lourdes Sanchez, F J Jaimenez-Balderas, J Aceves-Avila, P Martinez-Osuna, J Fuentes, F Medina, and A Fraga Measurement of damage in 210 Mexican patients with systemic lupus erythematosus: relationship with disease duration Lupus, February 1, 1998; 7(2): 119 - 123. [Abstract] [PDF]